Arabic Arabic English English French French German German
dark

HCmed Signs a Global Development Agreement with Global Biotechnology Leader CSL Behring

HCmed announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring’s plasma derived immunoglobulin administered via HCmed’s new generation vibrating-mesh nebulizing device. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Expansions and Hirings Spark Surge of Growth in BioCapital Region

Next Post

Sherlock Biosciences’ CRISPR SARS-CoV-2 Test Selected as Finalist in “On the Rise” and Honorable Mention in “Health and Pandemic Response” Categories of Fast Company’s 2021 World Changing Ideas Awards

Related Posts
Total
0
Share